Strong long-term data for Tremfya in plaque psoriasis

Johnson & Johnson’s (NYSE: JNJ) pharma arm, Janssen, has announced new long-term data from the open-label period of the Phase III VOYAGE 1 clinical trial of Tremfya (guselkumab).

Data on the biologic’s impact in moderate to severe plaque psoriasis are being presented at the 39th Fall Clinical Dermatology Conference in Las Vegas, Nevada.

After four years, 82% of those in a combined group of patients, including those initially randomized to Tremfya or to placebo, with crossover at week 16, achieved at least a 90% improvement in the Psoriasis Area Severity Index (PASI 90) scale.